Doxorubicin hydrochloride
Showing 1 - 25 of 3,210
Rhabdomyosarcoma, Child Trial (Doxorubicin Hydrochloride Liposome+Irinotecan, Temozolomide+Irinotecan+Vincristine)
Not yet recruiting
- Rhabdomyosarcoma, Child
- Doxorubicin Hydrochloride Liposome+Irinotecan
- Temozolomide+Irinotecan+Vincristine
- (no location specified)
Jul 13, 2022
Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance
Not yet recruiting
- Metastatic Leiomyosarcoma
- +5 more
- Computed Tomography
- +3 more
- (no location specified)
Feb 2, 2023
Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Tumor Trial in New Brunswick
Active, not recruiting
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- +2 more
- Cyclophosphamide
- +4 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 28, 2023
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma Trial in Houston
Active, not recruiting
- Metastatic Urothelial Carcinoma
- +2 more
- Doxorubicin Hydrochloride
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +4 more
-
Phoenix, Arizona
- +2 more
Jun 27, 2022
High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Pegylated Liposomal Doxorubicin, Doxorubicin, Anti-PD-1 mAb)
Recruiting
- High-Risk Localized Soft Tissue Sarcoma
- Pegylated Liposomal Doxorubicin
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 15, 2023
Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
- Brentuximab vedotin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 20, 2023
Advanced Breast Cancer Trial in Shijiazhuang (Doxorubicin HCl liposome injection)
Completed
- Advanced Breast Cancer
- Doxorubicin hydrochloride liposome injection
-
Shijiazhuang, ChinaThe Fourth Hospital of Hebei Medical University
Oct 18, 2023
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative Trial in Houston (Doxorubicin,
Recruiting
- Metastatic Kidney Medullary Carcinoma
- +4 more
- Doxorubicin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
Classical Hodgkin Lymphoma Trial in Seattle (drug, other, biological)
Recruiting
- Classical Hodgkin Lymphoma
- Dacarbazine
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 8, 2022
Locally Advanced or Metastatic Solid Tumors Trial in China (IN10018+PLD, IN10018+PLD+Toripalimab)
Active, not recruiting
- Locally Advanced or Metastatic Solid Tumors
-
Anyang, Henan, China
- +6 more
Apr 25, 2023
Sarcoma Trial in Baltimore, Minneapolis (biological, drug, procedure, radiation)
Active, not recruiting
- Sarcoma
- pegfilgrastim
- +5 more
-
Baltimore, Maryland
- +1 more
Mar 25, 2022
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal
Recruiting
- Platinum-Refractory Fallopian Tube Carcinoma
- +11 more
- Copanlisib Hydrochloride
- +4 more
-
Aurora, Colorado
- +2 more
Dec 8, 2022
Breast Cancer, Ovarian Cancer Trial in Guangzhou (Doxorubicin Hydrochloride Liposome Injection)
Recruiting
- Breast Cancer
- Ovarian Cancer
- Doxorubicin Hydrochloride Liposome Injection
-
Guangzhou, Guangdong, ChinaSun Yat-Sun Memorial Hospital, Sun Yat-Sun University
Mar 8, 2022
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma Trial in Portland (Doxorubicin
Active, not recruiting
- Advanced Soft Tissue Sarcoma
- +26 more
- Doxorubicin Hydrochloride
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Jan 6, 2023
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Advanced Malignant Tumors Trial in Shanghai (doxorubicin HCl liposome injection)
Recruiting
- Advanced Malignant Tumors
- doxorubicin hydrochloride liposome injection
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 28, 2022
Sarcoma, Soft Tissue Trial in Beijing (609A, doxorubicin HCl)
Not yet recruiting
- Sarcoma, Soft Tissue
- 609A
- doxorubicin hydrochloride
-
Beijing, Beijing, ChinaBeijing ji shui tan Hospital
Nov 17, 2021
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)
Not yet recruiting
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- +13 more
- (no location specified)
Feb 2, 2023
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma Trial in France (Bintrafusp alfa, Doxorubicin)
Recruiting
- Advanced Soft-tissue Sarcoma
- Metastatic Soft-tissue Sarcoma
- Bintrafusp alfa
- Doxorubicin
-
Bordeaux, France
- +7 more
Dec 6, 2021
Breast Cancer Trial in Worldwide (Liposomal doxorubicin HCl, Cyclophosphamide, Trastuzumab)
Completed
- Breast Cancer
- Liposomal doxorubicin hydrochloride
- +4 more
-
Kufstein, Austria
- +21 more
Jun 21, 2022
Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)
Not yet recruiting
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Glofitamab
- +5 more
-
Boston, Massachusetts
- +1 more
Apr 4, 2023
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer Trial in New
Suspended
- Estrogen Receptor-negative Breast Cancer
- +8 more
- pegylated liposomal doxorubicin hydrochloride
- +6 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Sep 20, 2021